SEARCH

SEARCH BY CITATION

References

  • Abelson MB (1998): Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. Ann Allergy Asthma Immunol 81: 211218.
  • Abelson M, Howes J & George M (1998): The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate. J Ocul Pharmacol Ther 14: 533542.
  • Alexander M, Berger W, Buchholz P, Walt J, Burk C, Lee J, Arbuckle R & Abetz L (2005): The reliability, validity, and preliminary responsiveness of the Eye Allergy Patient Impact Questionnaire (EAPIQ). Health Qual Life Outcomes 3: 67.
  • Alvarez-Cuesta E, Cuesta-Herranz J, Puyana-Ruiz J, Cuesta-Herranz C & Blanco-Quirós A (1994): Monoclonal antibody-standardized cat extract immunotherapy: risk-benefit effects from a double-blind placebo study. J Allergy Clin Immunol 93: 556566.
  • American Academy of Allergy, Asthma & Immunology (2000): The allergy report. Volume 3: conditions that may have an allergic component. Milwaukee, WI: American Academy of Allergy, Asthma & Immunology, 1158.
  • American Academy of Ophthalmology (2003): Conjunctivitis, preferred practice pattern. Available at: http://www.aao.org/ppp. Accessed September 19, 2008. San Francisco: CA, 141.
  • Armaly MF (1965): Statistical attributes of the steroid hypertensive response in the clinically normal eye. I. The demonstration of three levels of response. Invest Ophthalmol 4: 187197.
  • Asbell P & Howes J (1997): A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. CLAO J 23: 3136.
  • Barney NP & Graziano FM (2003): Allergic and immunologic diseases of the eye. In: Adkinson NFJ, Yunginger JW, Busse WW, Bochner BS, Holgate ST & Simons FE (eds). Middleton’s allergy: principles & practice, vol. 2. St. Louis, MO: Mosby, 15991617.
  • Bartlett JD, Horwitz B, Laibovitz R & Howes JF (1993a): Intraocular pressure response to loteprednol etabonate in known steroid responders. J Ocul Pharmacol 9: 157165.
  • Bartlett JD, Howes JF, Ghormley NR, Amos JF, Laibovitz R & Horwitz B (1993b): Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis. Curr Eye Res 12: 313321.
  • Belvisi MG & Hele DJ (2003): Soft steroids: a new approach to the treatment of inflammatory airways diseases. Pulm Pharmacol Ther 16: 321325.
  • Bhargava A, Jackson WB & El-Defrawy SR (1998): Ocular allergic disease. Drugs Today (Barc) 34: 957971.
  • Bielory L (2000): Allergic and immunologic disorders of the eye. Part I: immunology of the eye. J Allergy Clin Immunol 106: 805816.
  • Bielory L (2002a): Ocular allergy guidelines: a practical treatment algorithm. Drugs 62: 16111634.
  • Bielory L (2002b): Update on ocular allergy treatment. Expert Opin Pharmacother 3: 541553.
  • Bielory L (2006): Allergic diseases of the eye. Med Clin North Am 90: 129148.
  • Bielory L (2007): Differential diagnoses of conjunctivitis for clinical allergist-immunologists. Ann Allergy Asthma Immunol 98: 105114.
  • Bielory L (2008): Ocular allergy treatment. Immunol Allergy Clin North Am 28: 189224.
  • Bielory L & Friedlaender M (2008): Allergic conjunctivitis. Immunol Allergy Clin North Am 28: 4358.
  • Bielory L & Ghafoor S (2005): Histamine receptors and the conjunctiva. Curr Opin Allergy Clin Immunol 5: 437440.
  • Bielory L & Mongia A (2002): Current opinion of immunotherapy for ocular allergy. Curr Opin Allergy Clin Immunol 2: 447452.
  • Bielory L, Goodman PE & Fisher EM (2001): Allergic ocular disease. A review of pathophysiology and clinical presentations. Clin Rev Allergy Immunol 20: 183200.
  • Bielory L, Buddiga P & Bigelson S (2004): Ocular allergy treatment comparisons: azelastine and olopatadine. Curr Allergy Asthma Rep 4: 320325.
  • Bielory L, Katelaris CH, Lightman S & Naclerio RM (2007): Treating the ocular component of allergic rhinoconjunctivitis and related eye disorders. MedGenMed 9: 35.
  • Bodor N & Buchwald P (2005): Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems. AAPS J 7: E820E833.
  • Bousquet J, Khaltaev N, Cruz AA et al. (2008): Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 63(Suppl 86): 8160.
  • Broide DH (2007): The pathophysiology of allergic rhinoconjunctivitis. Allergy Asthma Proc 28: 398403.
  • Butrus S & Portela R (2005): Ocular allergy: diagnosis and treatment. Ophthalmol Clin North Am 18: 485492.
  • Carnahan MC & Goldstein DA (2000): Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol 11: 478483.
  • Chambless SL & Trocme S (2004): Developments in ocular allergy. Curr Opin Allergy Clin Immunol 4: 431434.
  • Chang J, McCluskey P & Wakefield D (2006): Toll-like receptors in ocular immunity and the immunopathogenesis of inflammatory eye disease. Br J Ophthalmol 90: 103108.
  • Dell SJ, Shulman DG, Lowry GM & Howes J (1997): A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group. Am J Ophthalmol 123: 791797.
  • Dell SJ, Lowry GM, Northcutt JA, Howes J, Novack GD & Hart K (1998): A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis. J Allergy Clin Immunol 102: 251255.
  • Donovan J, Buckeridge D, Briscoe M, Clark R & Day J (1996): Efficacy of immunotherapy to ragweed antigen tested by controlled antigen exposure. Ann Allergy Asthma Immunol 77: 7480.
  • Friedlaender MH & Howes J (1997): A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I. Am J Ophthalmol 123: 455464.
  • Holland EJ, Bartlett JD, Paterno MR, Usner DW & Comstock TL (2008): Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers. Cornea 27: 5055.
  • Holland E, Djalilian A & Sanderson J (2009): Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation. Cornea 28: 11391143.
  • Ilyas H, Slonim CB, Braswell GR, Favetta JR & Schulman M (2004): Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis. Eye Contact Lens 30: 1013.
  • Ito Y, Takahashi Y, Fujita T & Fukuyama S (1997): Clinical effects of immunotherapy on Japanese cedar pollinosis in the season of cedar and cypress pollination. Auris Nasus Larynx 24: 163170.
  • Jones R 3rd & Rhee DJ (2006): Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol 17: 163167.
  • Leibowitz HM, Bartlett JD, Rich R, McQuirter H, Stewart R & Assil K (1996): Intraocular pressure-raising potential of 1.0% rimexolone in patients responding to corticosteroids. Arch Ophthalmol 114: 933937.
  • Leonardi A (2002): The central role of conjunctival mast cells in the pathogenesis of ocular allergy. Curr Allergy Asthma Rep 2: 325331.
  • Leonardi A, Curnow SJ, Zhan H & Calder VL (2006): Multiple cytokines in human tear specimens in seasonal and chronic allergic eye disease and in conjunctival fibroblast cultures. Clin Exp Allergy 36: 777784.
  • Leonardi A, De Dominicis C & Motterle L (2007): Immunopathogenesis of ocular allergy: a schematic approach to different clinical entities. Curr Opin Allergy Clin Immunol 7: 429435.
  • Loteprednol Etabonate Postoperative Inflammation Study Group 2 (1998): A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. Ophthalmology 105: 17801786.
  • Loteprednol Etabonate US Uveitis Study Group (1999): Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Am J Ophthalmol 127: 537544.
  • Manabe S, Bucala R & Cerami A (1984): Nonenzymatic addition of glucocorticoids to lens proteins in steroid-induced cataracts. J Clin Invest 74: 18031810.
  • McGhee CN, Dean S & Danesh-Meyer H (2002): Locally administered ocular corticosteroids: benefits and risks. Drug Saf 25: 3355.
  • Meyer D (2006): Current concepts in the therapeutic approach to allergic conjunctivitis. Curr Allergy Clin Immunol 19: 6568.
  • Mindel JS, Tavitian HO, Smith H Jr & Walker EC (1980): Comparative ocular pressure elevation by medrysone, fluorometholone, and dexamethasone phosphate. Arch Ophthalmol 98: 15771578.
  • Novack GD (2002): Compared topical ocular olopatadine 0.1% (Patanol) and loteprednol etabonate 0.2% (Alrex) in an allergen challenge model. Clin Ther 24: 14771478; author reply 1478–1480.
  • Novack GD, Howes J, Crockett RS & Sherwood MB (1998): Change in intraocular pressure during long-term use of loteprednol etabonate. J Glaucoma 7: 266269.
  • Ono SJ & Abelson MB (2005): Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol 115: 118122.
  • Pearlman DS (1999): Pathophysiology of the inflammatory response. J Allergy Clin Immunol 104: S132S137.
  • Pitt AD, Smith AF, Lindsell L, Voon LW, Rose PW & Bron AJ (2004): Economic and quality-of-life impact of seasonal allergic conjunctivitis in Oxfordshire. Ophthalmic Epidemiol 11: 1733.
  • Schacke H, Docke WD & Asadullah K (2002): Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96: 2343.
  • Shulman DG, Lothringer LL, Rubin JM, Briggs RB, Howes J, Novack GD & Hart K (1999): A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis. Ophthalmology 106: 362369.
  • Singh K & Bielory L (2007a): Epidemiology of ocular allergy symptoms in United States adults (1988–1994). Abstract 35. Ann Allergy Asthma Immunol 98: A22.
  • Singh K & Bielory L (2007b): Ocular allergy: a national epidemiologic study. Abstract 604. J Allergy Clin Immunol 119: S154.
  • Smith AF, Pitt AD, Rodruiguez AE et al. (2005): The economic and quality of life impact of seasonal allergic conjunctivitis in a Spanish setting. Ophthalmic Epidemiol 12: 233242.
  • Spector S & Raizman M (1994): Conjunctivitis medicamentosa. J Allergy Clin Immunol 94: 134136.
  • Stahl JL & Barney NP (2004): Ocular allergic disease. Curr Opin Allergy Clin Immunol 4: 455459.
  • Stahn C, Lowenberg M, Hommes DW & Buttgereit F (2007): Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol 275: 7178.
  • The Medical Letter (2007): Drugs for some common eye disorders. Treat Guidel Med Lett 5: 18.
  • Tripathi RC, Parapuram SK, Tripathi BJ, Zhong Y & Chalam KV (1999): Corticosteroids and glaucoma risk. Drugs Aging 15: 439450.
  • Urban RC Jr & Dreyer EB (1993): Corticosteroid-induced glaucoma. Int Ophthalmol Clin 33: 135139.
  • Wallace DV, Dykewicz MS, Bernstein DI et al. (2008): The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 122: S1S84.
  • White EM, Macy JI, Bateman KM & Comstock TL (2008): Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis. Curr Med Res Opin 24: 287296.
  • Woodward DF, Nieves AL, Williams LS, Gary RK Jr, Wasserman MA & Gleason JG (1989): Interactive effects of peptidoleukotrienes and histamine on microvascular permeability and their involvement in experimental cutaneous and conjunctival immediate hypersensitivity. Eur J Pharmacol 164: 323333.
  • Woodward DF, Nieves AL, Hawley SB, Joseph R, Merlino GF & Spada CS (1995): The pruritogenic and inflammatory effects of prostanoids in the conjunctiva. J Ocul Pharmacol Ther 11: 339347.